Skip to main content

Table 1 Baseline patient demographic and clinical characteristics

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

  CCRT with cetuximab group (n = 62) CCRT group (n = 124) P value
Age, years    1
 Mean 46.32 (25–64) 46.05 (28–66)  
Sex    1
 Male 50 (80.6%) 100 (80.6%)  
 Female 12 (19.4%) 24 (19.4%)  
Pathological type    1
 WHO type II 3 (4.8%) 4 (3.2%)  
 WHO type III 59 (95.2%) 120 (96.8%)  
T category    1
 T2 14 (22.6%) 28 (22.6%)  
 T3 41 (66.1%) 82 (66.1%)  
 T4 7 (11.3%) 14 (11.3%)  
N category    1
 N0 6 (9.7%) 12 (9.7%)  
 N1 25 (40.3%) 50 (40.3%)  
 N2 28 (45.2%) 56 (45.2%)  
 N3 3 (4.8%) 6 (4.8%)  
Disease stage    1
 II 5 (8.1%) 10 (8.1%)  
 III 47 (75.8%) 94 (75.8%)  
 IVA 7 (11.3%) 14 (11.3%)  
 IVB 3 (4.8%) 6 (4.8%)  
RT technique    1
 2DRT 10 (16.1%) 20 (16.1%)  
 IMRT 52 (83.9%) 104 (83.9%  
Cisplatin delivery    0.144
 Every 3 weeks(80–100 mg/m2) 39 (62.9%) 64 (51.6%)  
 Weekly (30–40 mg/m2) 23 (37.1%) 60 (48.4%)  
EBV DNA level    1
  < 4000 copies 35 (56.5%) 70 (56.5%)  
  ≥ 4000 copies 27 (43.5%) 54 (43.5%)  
VCA-IgA    1
  < 1:80 15 (24.2%) 30 (24.2%)  
  ≥ 1:80 47 (75.8%) 94 (75.8%)  
EA-IgA    0.148
  < 1:10 24 (38.7%) 35 (28.2%)  
  ≥ 1:10 38 (61.3%) 89 (71.8%)  
ECOG    1
 0 1 (1.6%) 2 (1.6%)  
 1 61 (98.4%) 122 (98.4%)  
LDH,U/L    0.666
  < 245 61 (98.4%) 120 (96.8%)  
  ≥ 245 1 (1.6%) 4 (3.2%)  
CRP,g/ml    0.286
  < 3.00 49 (79.0%) 89 (71.8%)  
  ≥ 3.00 13 (21.0%) 35 (28.2%)  
Body mass index, kg/m2    1
  < 18.5 3 (4.8%) 5 (4.0%)  
  ≥ 18.5 59 (95.2%) 119 (96.0%)  
Smoking    0.46
 Yes 20 (32.2%) 59 (47.6%)  
 No 42 (67.7%) 65 (52.4%)  
Family history of cancer    0.02
 Yes 13 (21.0%) 11 (8.9%)  
 No 49 (79.0%) 113 (91.1%)  
  1. Abbreviations: CCRT concurrent chemoradiotherapy, WHO World Health Organization, 2DRT two-dimensional radiotherapy, IMRT intensity-modulated radiotherapy, EA early antigen, VCA viral capsid antigen, IgA immunoglobulin A, EBV DNA Epstein-Barr virus DNA, ECOG Eastern Cooperative Oncology Group, CRP C-reactive protein, LDH serum lactate dehydrogenase levels